Pathology: breast cancer - adjuvant; es-BC - HER2 negative - (neo)adjuvant (NA); es-BC - TNBC - NA - all population; mBC - TNBC - L1 - all population; mBC - TNBC - L1 - PDL1 positive; mBC - TNBC - L2 - all population; mBC - TNBC - L2 - PDL1 positive;
breast cancer - adjuvant | es-BC - HER2 negative - (neo)adjuvant (NA) | es-BC - TNBC - NA - all population | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | mBC - TNBC - L2 - all population | mBC - TNBC - L2 - PDL1 positive | ||||
KEYNOTE-522, 2020 | I-SPY2, 2020 | KEYNOTE-522, 2020 | KEYNOTE-355 (all population), 2020 | KEYNOTE-355 (CPS>1), 2020 | KEYNOTE-355 (CPS>10), 2020 | KEYNOTE-119 (all population), 2019 | KEYNOTE-119 (PDL1 CPS>10), 2019 | KEYNOTE-119 (PDL1 CPS>1), 2019 | ||
pembrolizumab alone | 5 | T1 | T1 | T1 | T1 | T1 | ||||
pembrolizumab plus SoC | 3 | T1 | T1 | T1 | ||||||
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide | 1 | T1 | ||||||||
placebo | 0 | T0 | T0 | |||||||
paclitaxel followed by doxorubicin plus cyclophosphamide | 0 | T0 | ||||||||
placebo plus SoC | 0 | T0 | T0 | T0 | ||||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 |